134 related articles for article (PubMed ID: 21609295)
1. CCR1 as a target for multiple myeloma.
Vallet S; Anderson KC
Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
[TBL] [Abstract][Full Text] [Related]
2. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of CCR1 antagonists for multiple myeloma.
Karash AR; Gilchrist A
Future Med Chem; 2011 Nov; 3(15):1889-908. PubMed ID: 22023033
[TBL] [Abstract][Full Text] [Related]
4. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
5. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
[TBL] [Abstract][Full Text] [Related]
6. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
[TBL] [Abstract][Full Text] [Related]
7. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
[TBL] [Abstract][Full Text] [Related]
8. CCR1 blockade and myeloma bone disease.
Sebag M
Blood; 2012 Aug; 120(7):1351-2. PubMed ID: 22899473
[TBL] [Abstract][Full Text] [Related]
9. Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.
Gilchrist A; Gauntner TD; Fazzini A; Alley KM; Pyen DS; Ahn J; Ha SJ; Willett A; Sansom SE; Yarfi JL; Bachovchin KA; Mazzoni MR; Merritt JR
Br J Pharmacol; 2014 Nov; 171(22):5127-38. PubMed ID: 24990525
[TBL] [Abstract][Full Text] [Related]
10. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma.
Gilchrist A; Echeverria SL
Front Endocrinol (Lausanne); 2022; 13():846310. PubMed ID: 35399952
[TBL] [Abstract][Full Text] [Related]
11. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
Vallet S; Raje N; Ishitsuka K; Hideshima T; Podar K; Chhetri S; Pozzi S; Breitkreutz I; Kiziltepe T; Yasui H; Ocio EM; Shiraishi N; Jin J; Okawa Y; Ikeda H; Mukherjee S; Vaghela N; Cirstea D; Ladetto M; Boccadoro M; Anderson KC
Blood; 2007 Nov; 110(10):3744-52. PubMed ID: 17715391
[TBL] [Abstract][Full Text] [Related]
12. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Oyajobi BO; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment.
Liu L; Yu Z; Cheng H; Mao X; Sui W; Deng S; Wei X; Lv J; Du C; Xu J; Huang W; Xia S; An G; Zhou W; Ma X; Cheng T; Qiu L; Hao M
Sci Rep; 2020 Nov; 10(1):20508. PubMed ID: 33239656
[TBL] [Abstract][Full Text] [Related]
14. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
15. [Effect of CCL3 on osteoblast in myeloma bone disease].
Zhao S; Fu R; Liu H; Wang Y; Li L; Liu C; Zhang T; Ding S; Gao S; Ruan E; Qu W; Wang H; Wang X; Wu Y; Song J; Liu H; Guan J; Shao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):623-7. PubMed ID: 25052606
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies for bone disease.
Roodman GD
Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
18. Evidences of the cooperative role of the chemokines CCL3, CCL4 and CCL5 and its receptors CCR1+ and CCR5+ in RANKL+ cell migration throughout experimental periodontitis in mice.
Repeke CE; Ferreira SB; Claudino M; Silveira EM; de Assis GF; Avila-Campos MJ; Silva JS; Garlet GP
Bone; 2010 Apr; 46(4):1122-30. PubMed ID: 20053385
[TBL] [Abstract][Full Text] [Related]
19. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.
Vandyke K; Zeissig MN; Hewett DR; Martin SK; Mrozik KM; Cheong CM; Diamond P; To LB; Gronthos S; Peet DJ; Croucher PI; Zannettino ACW
Cancer Res; 2017 Oct; 77(20):5452-5463. PubMed ID: 28855206
[TBL] [Abstract][Full Text] [Related]
20. Role of C-C chemokine receptors 1 and 5 and CCL3/macrophage inflammatory protein-1alpha in the cutaneous Arthus reaction: possible attenuation of their inhibitory effects by compensatory chemokine production.
Yanaba K; Mukaida N; Matsushima K; Murphy PM; Takehara K; Sato S
Eur J Immunol; 2004 Dec; 34(12):3553-61. PubMed ID: 15517609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]